New class of lipid-lowering medication shows lasting LDL-c lowering in dose-finding study - PACE-CME

New class of lipidlowering medication shows lasting LDLc lowering in dosefinding study

Media formats available:

Ready to Claim Your Credits?

You have attempts to pass this post-test. Take your time and review carefully before submitting.

Good luck!

Recommended

Icosapent ethyl in post-CABG patients with diabetes
Icosapent ethyl in post-CABG patients with diabetes
Hyperlipidemia
Icosapent ethyl in post-CABG patients with diabetes
- Subodh Verma, MD, PhD
Phase 3 study results of plozasiran in patients with FCS
Phase 3 study results of plozasiran in patients with FCS
Hyperlipidemia
Phase 3 study results of plozasiran in patients with FCS
- Gerald F. Watts, DSc, DM, PhD
New ESC Guidelines for CCS and PAAD
New ESC Guidelines for CCS and PAAD
ESC Congress 2024
New ESC Guidelines for CCS and PAAD
- Pierre Sabouret, MD, PhD
Predicting 30-year CV outcomes in women
Predicting 30-year CV outcomes in women
ESC Congress 2024
Predicting 30-year CV outcomes in women
- Paul Ridker, MD